Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6675945 | 0.98 | HRH3 (0.64) | HRH3TAAR1GFERSIGMAR1MAOB | |
| SCHEMBL5708331 | 0.98 | HRH3 (0.64) | HRH3TAAR1GFERSIGMAR1MAOB | |
| SCHEMBL18762839 | 0.87 | HRH3 (0.84) | HRH3TAAR1SIGMAR1AOC3ALDH1A1 | |
| SCHEMBL1728762 | 0.86 | GFER (0.54) | HRH3TAAR1GFERSIGMAR1MAOB | |
| SCHEMBL9627913 | 0.86 | SIGMAR1 (0.66) | HRH3TAAR1GFERSIGMAR1MAOB | |
| Hydrochloric Acid SCHEMBL3563729 | 0.85 | MAOB (0.55) | HRH3TAAR1GFERSIGMAR1MAOB | |
| SCHEMBL8076000 | 0.85 | SIGMAR1 (0.62) | HRH3TAAR1GFERSIGMAR1MAOB | |
| SCHEMBL15807549 | 0.83 | SIGMAR1 (0.66) | HRH3GFERSIGMAR1MAOB | |
| SCHEMBL27274534 | 0.80 | SIGMAR1 (0.56) | HRH3GFERSIGMAR1MAOBMAOA | |
| SCHEMBL18789268 | 0.80 | GFER (0.65) | HRH3GFERSIGMAR1MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-06-12 | — | — | US | disclosed |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| US-12220415-B2 | WEE1 kinase inhibitors and methods of treating cancer using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-02-11 | — | — | US | disclosed |
| CN-118176195-A | Pyrazolo [3,4-d ] pyrimidine-3-ketone compound and medical application thereof | 正大天晴药业集团股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023237759-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR | ANAGENESIS BIOTECHNOLOGIES (FR) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023237759-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR | ANAGENESIS BIOTECHNOLOGIES (FR) | 2023-12-14 | — | — | WO | disclosed |
| EP-4289427-A1 | DIHYDRO[1,8]NAPHTHYRIDIN-7-ONE AND PYRIDO[3,2-B][1,4]OXAZIN-3-ONE FOR USE IN TREATING CANCER, AND METASTASES IN PARTICULAR. | Anagenesis Biotechnologies (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-20230391730-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2023-12-07 | — | — | US | disclosed |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-6291470-B1 | DELTA-OPIOID ANTAGONIST HAVING HIGH SELECTIVITY AND ACTIVITY, THAT EXHIBITS IMMUNOSUPPRESSIVE ACTION, ANTIALLERGIC ACTION, ANTI-INFLAMMATORY ACTION AND BRAIN CELL-PROTECTING ACTION | TORAY INDUSTRIES, INC. (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-1115704-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | Boehringer Ingelheim Pharma KG (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001027080-A2 | 5-SUBSTITUTED INDOLINONES AND USE THEREOF AS KINASE AND CYCLIN/CDK COMPLEX INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
| WO-2001016130-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-08 | — | — | WO | disclosed |
| WO-2000040565-A1 | TETRAHYDROINDAZOLE DERIVATIVES AS LIGANDS FOR GABA-A ALPHA 5 RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 2000-07-13 | — | — | WO | disclosed |
| US-6087369-A | AN IMMUNOSUPPRESSIVE AGENT, ANTIALLERGIC AGENT, ANTI-INFLAMMATORY AGENT AND BRAIN CELL-PROTECTING AGENT | TORAY INDUSTRIES, LTD. (JP) | 2000-07-11 | — | — | US | disclosed |
| WO-2000018734-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-04-06 | — | — | WO | disclosed |
| EP-0614898-A1 | INDOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1994-09-14 | — | — | EP | disclosed |
| US-4431585-A | THIAZOLE AND THIOPHENE DYES; DIAZOTIZATION; COUPLING | CASSELLA AKTIENGESELLSCHAFT (DE) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220415-B2 | WEE1 kinase inhibitors and methods of treating cancer using the same | WEE1, WEE2, NME1 | HRH3 2958/4885TAAR1 4678/4885GFER 3742/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | HRH3 1706/4885TAAR1 2099/4885GFER 2160/4885 |
| US-20230372297-A1 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES | MMP1, COL1A1, SMAD3 | HRH3 380/4885TAAR1 1492/4885GFER 2585/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | HRH3 1706/4885TAAR1 2099/4885GFER 2160/4885 |
| US-20250186447-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | WEE1, WEE2, NME1 | HRH3 2958/4885TAAR1 4678/4885GFER 3742/4885 |
| US-20230391730-A1 | INHIBITORS OF THE BROMODOMAIN PHD FINGER TRANSCRIPTION FACTOR (BPTF) AS ANTI-CANCER AGENTS | BPTF, BRPF3, PHF6 | HRH3 254/4885TAAR1 1598/4885GFER 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.